Russell Frank Company’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Russell Frank Company’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-951	Closed	-$1.43M	–	3045
2014 Q3	$1.43M	Buy	+951	New	+$1.38M	﹤0.01%	1902
2014 Q2	–	Sell	-482	Closed	-$509K	–	2870
2014 Q1	$509K	Buy	+482	New	+$560K	﹤0.01%	2376
2013 Q4	–	Sell	-16	Closed	-$17K	–	3099
2013 Q3	$17K	Sell	16 -374	-96%	-$400K	﹤0.01%	3252
2013 Q2	$426K	Buy	+390	New	+$435K	﹤0.01%	2373

Other funds holding VIRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Russell Frank Company's VIRX Position: Q4 2014 in Review

Russell Frank Company sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 951 shares — an estimated $1.43M sold.

Russell Frank Company first reported a position in VIRX in Q2 2013 and held it in 4 quarters. The position peaked at $1.43M in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

Russell Frank Company reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
Russell Frank Company sold 951 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $1.43M.
Russell Frank Company first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
Russell Frank Company's Viracta Therapeutics, Inc. Common Stock position peaked at $1.43M in Q3 2014.
78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Russell Frank Company's 13F filing for Q4 2014, filed 5 Feb 2015.